After things have been going very well with equity investments recently, I added 2 new opportunities to my portfolio yesterday, with a target of at least 100%.

The first would be $GPCR . A biotech company. Developed in the slimming market. According to initial studies, the preparation is said to have improved the effectiveness of $NOVO B (-2,31 %) and $LLY (-2,68 %) in some areas.

In addition to the chance of positive market launches, I also see good opportunities for takeovers by pharmaceutical giants who also want a foothold in the market.